The U.S. Food and Drug Administration (FDA) will convene an advisory panel to evaluate whether compounding pharmacies should be allowed to manufacture certain peptides, according to regulatory sources familiar with the matter. The meeting, expected in the coming months, could expand access to these substances, which are increasingly used in medical and wellness treatments.
Peptides—short chains of amino acids—have gained attention for their potential therapeutic benefits, including muscle growth, anti-aging, and metabolic regulation. Currently, many peptides fall into a regulatory gray area, with some available only through clinical trials or off-label prescriptions. The FDA has historically restricted compounding pharmacies from producing them due to safety and efficacy concerns.
“This is a pivotal moment for peptide access,” said a pharmaceutical analyst who requested anonymity. “If the panel recommends loosening restrictions, it could open the door for more widespread use, but regulators will have to balance innovation with patient safety.”
Opponents argue that allowing broader compounding could lead to inconsistent quality and potential misuse. The FDA has previously warned about unapproved peptide products being marketed with unsubstantiated health claims. However, proponents contend that expanded access would benefit patients who rely on these compounds for chronic conditions.
The outcome of the panel’s discussion could influence future FDA guidance on peptide regulation, setting a precedent for how emerging biopharmaceuticals are handled in the U.S.